Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About DHAI Interactive Breakdown Better Bets vs. DHAI Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

DIH US (DHAI)

Market Price (10/31/2025): $1.98 | Market Cap: $3.1 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

DIH US (DHAI)

Market Price (10/31/2025): $1.98
Market Cap: $3.1 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0  Weak multi-year price returns
2Y Excs Rtn is -164%, 3Y Excs Rtn is -176%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -5.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.2%
1   Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 425%
2   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.7%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.5%
3   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -299%
4   High stock price volatility
Vol 12M is 2746%
0 Weak multi-year price returns
2Y Excs Rtn is -164%, 3Y Excs Rtn is -176%
1 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -5.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.2%
2 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 425%
3 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.7%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -7.5%
4 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -299%
5 High stock price volatility
Vol 12M is 2746%

Market Valuation & Key Metrics

null

DHAI Stock

   
   
   
   
   
   
   
Factor Drivers of Stock Movement
The -59.7% change in DHAI stock from 5/1/2025 to 10/30/2025 was primarily driven by a -13.4% change in the company's Shares Outstanding (Mil).

501202510302025Change
Stock Price ($)4.821.94-59.73%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)�62.09�
P/S Multiple�0.05�
Shares Outstanding (Mil)1.391.57-13.40%
Cumulative Contribution�

LTM = Last Twelve Months as of date shown
The -94.0% change in DHAI stock from 10/30/2024 to 10/30/2025 was primarily driven by a -13.7% change in the company's Shares Outstanding (Mil).

1030202410302025Change
Stock Price ($)32.251.94-93.98%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)�62.09�
P/S Multiple�0.05�
Shares Outstanding (Mil)1.381.57-13.72%
Cumulative Contribution�

LTM = Last Twelve Months as of date shown
null

null

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
DHAI Return----56%-69%-94%-99%
Peers Return42%3%-9%-5%-14%-18%-12%
S&P 500 Return16%27%-19%24%23%16%110%

Monthly Win Rates [3]
DHAI Win Rate--89%83%50%33% 
Peers Win Rate40%33%32%28%42%47% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
DHAI Max Drawdown----57%-83%-100% 
Peers Max Drawdown-25%-12%-25%-25%-21%-44% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: A, ATEC, CERS, BDMD, PTHL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique KeyEventDHAIS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-59.9%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven149.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days

Compare to A, ATEC, CERS, BDMD, PTHL


In The Past

DIH US's stock fell -59.9% during the 2022 Inflation Shock from a high on 12/12/2023. A -59.9% loss requires a 149.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About DIH US (DHAI)

Better Bets than DIH US (DHAI)

 DHAIBetter Performance than DHAI
MetricValueIndustry (Life Sciences Tools & Services)
Op Mgn LTM-9.2%TMO (18.2%), DHR (19.0%), A (21.3%), IQV (14.2%), MTD (28.4%)
CFO/Rev LTM-6.7%TMO (17.5%), DHR (26.0%), A (22.0%), IQV (17.6%), MTD (24.6%)
FCF/Rev LTM-7.5%TMO (14.3%), DHR (20.7%), A (16.0%), IQV (13.9%), MTD (21.9%)
Total Yield-294.6%TMO (3.1%), DHR (2.3%), A (3.7%), IQV (3.5%), MTD (2.9%)
 DHAIBetter Performance than DHAI
MetricValueAll Other Sectors
Op Mgn LTM-9.2%NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
CFO/Rev LTM-6.7%NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM-7.5%NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield-294.6%NVDA (1.8%), AAPL (2.8%), MSFT (3.3%), GOOGL (3.9%), AMZN (3.0%)
 Best Bets In Health Care Sector
 DHAIRPRX HALO CPRX BMY LNTH PBH BIIB PFE EW ILMN
What You Pay           
P/E-0.315.314.112.315.414.014.013.612.811.812.4
P/EBIT-0.38.111.010.59.39.69.010.110.329.210.3
What You Get           
Rev Chg Q�7.7%40.8%19.4%2.8%-4.1%-6.6%2.8%10.3%11.9%-4.8%
Rev Chg LTM�3.0%35.0%28.5%1.3%5.7%0.6%4.8%13.5%9.1%-3.3%
Rev Chg 3Y Avg�0.8%35.5%49.9%1.0%34.3%0.8%-0.9%-12.4%3.0%-3.0%
FCF/Rev 3Y Avg�113.4%43.4%38.9%29.0%26.1%21.6%17.0%13.8%11.9%9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Trade Ideas

Select past ideas related to DHAI. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PRAXPraxis Precision Medicines279.1%161.2%
2INBXInhibrx Biosciences131.0%409.8%
3PUMPProPetro99.6%16.2%
4DYNDyne Therapeutics88.4%-0.0%
5VICRVicor85.4%89.2%
6CELCCelcuity74.6%503.2%
7GLUEMonte Rosa Therapeutics73.5%87.5%
8NVTSNavitas Semiconductor72.1%251.8%
9LUMNLumen Technologies70.3%94.7%
10BALYBallys63.4%4.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical-62.9%5106.3%
2LRNStride-53.8%-35.8%
3FMCFMC-51.0%-66.6%
4FIFiserv-48.3%-68.3%
5NFENew Fortress Energy-43.6%-91.9%
6VGVenture Global-41.7% 
7OGNOrganon-40.2%-55.0%
8VRNSVaronis Systems-39.5%-21.2%
9ITGRInteger-38.5%-52.2%
10LENZLENZ Therapeutics-37.9%5.5%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for DIH US

Financials

DHAIAATECCERSBDMDPTHLMedian
NameDIH US Agilent .Alphatec Cerus Baird Me.Pheton  
Mkt Price1.94143.3616.331.401.400.631.67
Mkt Cap0.040.72.40.3--1.4
Rev LTM626,788682193--437
Op Inc LTM-61,444-95-12---9
FCF LTM-51,088-323---1
FCF 3Y Avg-1,308-123-16---16
CFO LTM-41,495166--11
CFO 3Y Avg-1,662-45-13---13

Growth & Margins

DHAIAATECCERSBDMDPTHLMedian
NameDIH US Agilent .Alphatec Cerus Baird Me.Pheton  
Rev Chg LTM-4.5%26.3%13.3%--13.3%
Rev Chg 3Y Avg-0.8%33.0%7.8%--7.8%
Rev Chg Q-10.1%27.5%16.3%--16.3%
QoQ Delta Rev Chg LTM-2.4%6.2%4.0%--4.0%
Op Mgn LTM-9.2%21.3%-13.9%-6.1%---7.6%
Op Mgn 3Y Avg-21.5%-24.2%-13.8%---13.8%
QoQ Delta Op Mgn LTM--0.1%4.2%0.5%--0.5%
CFO/Rev LTM-6.7%22.0%2.3%3.0%--2.6%
CFO/Rev 3Y Avg-24.6%-9.6%-8.2%---8.2%
FCF/Rev LTM-7.5%16.0%-4.6%1.8%---1.4%
FCF/Rev 3Y Avg-19.4%-24.6%-10.2%---10.2%

Valuation

DHAIAATECCERSBDMDPTHLMedian
NameDIH US Agilent .Alphatec Cerus Baird Me.Pheton  
Mkt Cap0.040.72.40.3--1.4
P/S0.06.03.61.4--2.5
P/EBIT-0.326.9-18.6-26.7---9.4
P/E-0.333.4-14.7-14.2---7.3
P/CFO-0.727.2156.046.9--37.1
Total Yield-294.6%3.7%-6.8%-7.0%---6.9%
Dividend Yield0.0%0.7%0.0%0.0%--0.0%
FCF Yield 3Y Avg-3.7%-7.3%-4.2%---4.2%
D/E4.90.10.20.4--0.3
Net D/E4.20.00.20.1--0.1

Returns

DHAIAATECCERSBDMDPTHLMedian
NameDIH US Agilent .Alphatec Cerus Baird Me.Pheton  
1M Rtn-58.5%11.7%12.3%-11.9%-34.0%-19.5%-15.7%
3M Rtn-65.7%25.1%54.3%9.4%-31.4%-29.6%-10.1%
6M Rtn-59.7%35.2%47.6%7.7%-74.8%-83.7%-26.0%
12M Rtn-94.0%9.9%190.6%-18.6%-49.1%-85.1%-33.8%
3Y Rtn-99.2%5.9%59.5%-61.7%---27.9%
1M Excs Rtn-61.4%1.8%15.2%-9.6%-36.2%-21.6%-15.6%
3M Excs Rtn-78.2%17.2%9.2%0.9%-36.1%-32.0%-15.6%
6M Excs Rtn-81.5%13.5%25.9%-14.0%-96.5%-105.5%-47.8%
12M Excs Rtn-111.8%-7.3%192.7%-35.8%-70.5%-103.6%-53.1%
3Y Excs Rtn-176.0%-67.8%-18.7%-137.9%---102.9%

Financials

$ Mil | FY: 3/312025Q42025Q32025Q22025Q1
Period End3/31/202512/31/20249/30/20246/30/2024
Filing Date10/20/20252/14/202511/15/20248/19/2024
Key Financials Quarterly    
Total Revenue13151816
Ebitda-5-30-2
Operating Income-3-32-2
Net Income-4-4-0-1
EPS-2.80-2.75-0.25-0.50
Key Financials TTM    
Total Revenue TTM62---
Ebitda TTM-9---
Operating Income TTM-6---
Net Income TTM-9---
Growth Rates Quarterly    
Total Revenue Growth----
EBITDA Growth----
Operating Income Growth----
Net Income Growth----
Margins Quarterly    
EBITDA Margin-40.0%-20.4%2.1%-9.7%
Operating Income Margin-25.4%-18.2%10.4%-10.2%
Net Income Margin-34.8%-24.7%-1.3%-3.8%
Cash & Debt    
Total Cash2123
Total Debt15151718
Net Debt / (Cash)13141515
Cash Flows Quarterly    
FCF from Operations-310-2
Cash Flows TTM    
FCF from Operations TTM-4---
Returns to Shareholders Quarterly    
Dividends0000
Share Repurchases-0-0-0-0
Return on Invested Capital (ROIC) Quarterly    
ROIC-52.9%-70.8%46.8%-39.2%
Return on Invested Capital (ROIC) TTM    
ROIC TTM-29.0%---

Price Behavior

DHAI Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta2.961.412.540.801.040.66
Up Beta14.508.477.75-0.56-0.20-0.07
Down Beta14.372.521.892.362.441.79
Up Capture-346%-148%-26%99%-9%-3%
Bmk +ve Days13233574144420
Stock +ve Days9182654100274
Down Capture389%-52%204%165%155%106%
Bmk -ve Days8192952107330
Stock -ve Days11233668140270

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity19,071
Short Interest: % Change Since 9302025-92.2%
Average Daily Volume1,259,254
Days-to-Cover Short Interest1
Basic Shares Quantity1,571,428
Short % of Basic Shares1.2%

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/20/2025-12.9%-23.4% 
2/14/2025-1.9%-29.0%-49.7%
11/14/20245.5%5.5%44.5%
7/15/20245.0%4.2%-29.6%
4/30/2024-1.9%3.8%-2.5%
2/20/20245.2%-33.0%4.3%
SUMMARY STATS   
# Positive332
# Negative334
Median Positive5.2%4.2%24.4%
Median Negative-1.9%-29.0%-29.6%
Max Positive5.5%5.5%44.5%
Max Negative-12.9%-33.0%-49.7%

SEC Filings

Expand for More

Report DateFiling DateFiling
33120251020202510-K 3/31/2025
12312024214202510-Q 12/31/2024
93020241115202410-Q 9/30/2024
6302024819202410-Q 6/30/2024
3312024715202410-K 3/31/2024
12312023429202410-K 12/31/2023
33120238042023S-4/A 3/31/2023
12312022520202410-K/A 12/31/2022

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.